C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl -ketoheterocycles

Authors: Furlong S.T.; Dutta A.S.; Coath M.M.; Gormley J.J.; Hubbs S.J.; Lloyd D.; Mauger R.C.; Strimpler A.M.; Sylvester M.A.; Scott C.W.; Edwards P.D.

Source: Immunopharmacology, Volume 48, Number 2, 20 July 2000 , pp. 199-212(14)

Publisher: Elsevier

Keywords: Complement; Compstatin; C3 convertase; C3

Language: English

Document Type: Research article

DOI: http://dx.doi.org/10.1016/S0162-3109(00)00205-8

Affiliations: 1: aAstraZeneca Pharmaceuticals, 1800 Concord Pike, , Wilmington, DE, USA

Publication date: 2000-07-20

• In this: publication
• By this: publisher
• In this Subject: Microbiology ,  Allergy & Immunology ,  Pharmacology
• By this author: Furlong S.T. ;  Dutta A.S. ;  Coath M.M. ;  Gormley J.J. ;  Hubbs S.J. ;  Lloyd D. ;  Mauger R.C. ;  Strimpler A.M. ;  Sylvester M.A. ;  Scott C.W. ;  Edwards P.D.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers